IMpower 132: Atezolizumab in Combination With Pemetrexed and Platinum-Based Chemotherapy in Advanced Nonsquamous NSCLC
The phase III IMpower132 study met its co-primary endpoint of progression-free survival and demonstrated that the combination of atezolizumab (Tecentriq) plus chemotherapy (cisplatin or carboplatin plus pemetrexed [Alimta]) reduced the risk of disease worsening or death compared to chemotherapy alone in the first-line treatment of advanced nonsquamous non–small cell lung cancer (NSCLC).
Although a numerical improvement for the co-primary endpoint of overall survival was observed, statistical significance was not met at this interim analysis, and the study will continue as planned with final overall survival results expected next year. Safety for the atezolizumab and chemotherapy combination appeared consistent with the known safety profile of the individual medicines, and no new safety signals were identified with the combination. These data will be presented at an upcoming medical meeting.
More About IMpower132
IMpower132 is a phase III, open-label, randomized study evaluating the efficacy and safety of atezolizuamb plus chemotherapy (cisplatin or carboplatin and pemetrexed) vs chemotherapy alone in chemotherapy-naive patients with advanced nonsquamous NSCLC. The study enrolled 578 people who were randomized equally (1:1) to receive atezolizumab in combination with cisplatin or carboplatin and pemetrexed (Arm A), or cisplatin or carboplatin and pemetrexed (Arm B, control arm).
During the treatment-induction phase, people received atezolizumab, pemetrexed, and investigator’s choice of either cisplatin or carboplatin on day 1 of every 3 weeks for a dosing period of 4 or 6 cycles. People who experienced clinical benefit during the induction phase began maintenance therapy until disease progression.
The co-primary endpoints were progression-free survival, as determined by the investigator using Response Evaluation Criteria in Solid Tumors, version 1.1, and overall survival. IMpower132 met its progression-free survival co-primary endpoint as per the study protocol.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
